Clinical trials
Every registered trial of PT-141 (Bremelanotide)
10 studies.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on PT-141 (Bremelanotide) has been registered.
- 10 registered studies in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 10 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 2,644 people took part in those.
How far along it is
- 5 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 4 have published results in the medical literature that anyone can read.
- The research spans 4 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 10 of 10 trials for PT-141 (Bremelanotide).
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
Cosette Pharmaceuticals, Inc.
Lactating Mother
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc
Obesity
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc
Kidney Disease
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Imperial College Healthcare NHS Trust
Hypoactive Sexual Desire Disorder
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
AMAG Pharmaceuticals, Inc.
Nausea
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Palatin Technologies, Inc
Sexual Arousal Disorder
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when PT-141 (Bremelanotide) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.